纤溶酶原激活剂抑制物-1基因启动子区-6754G/5G多态性与中国人冠心病的关联研究

Association of plasminogen activator inhibitor-1 gene 4G/5G polymorphism and coronary heart disease in Chinese patients

目的 研究纤溶酶原激活剂抑制物 - 1(plasminogen activator inhibitor- 1,PAI- 1)基因启动子区 - 6 75 4 G/ 5 G多态性与中国人冠状动脉粥样硬化性心脏病 (coronary heartdisease,CHD,简称冠心病 )发病的关系。方法 应用聚合酶链反应 -限制性片段长度多态性分析 ,对 12 1名健康人和 12 6例冠心病患者(其中急性心肌梗塞 4 7例 ,陈旧性心肌梗塞 39例 ,心绞痛 4 0例 )进行了 PAI- 1基因 4 G/ 5 G多态性分析。结果 PAI- 1基因 4 G等位基因频率冠心病组 (0 .6 0 )显著高于正常对照组 (0 .4 8) (χ2 =7.6 3,P<0 .0 1) ;4 G/4 G基因型基因频率冠心病组 (0 .397)显著高于正常对照组 (0 .190 ) (χ2 =12 .6 7,P<0 .0 1) ,与 5 G/ 5 G基因型相比 ,对冠心病的比数比 (odds ratio,OR)为 2 .5 4 ,95 %的可信区间 (confidence interval,CI) :1.2 2～ 5 .2 7(P<0 .0 5 ) ,差异有显著性 ,而 4 G/ 5 G基因型对冠心病的 OR为 1.2 8,95 % CI:1.4 5～ 2 .38(P>0 .0 5 ) ,差异无显著性。结论 PAI- 1基因 4 G/ 4 G基因型与中国汉族人冠心病的发病有关联 ,4 G/ 4

Objective: To assess whether the plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G polymorphism is associated with coronary heart disease (CHD) in Chinese patients. Methods: PAI-1 gene 4G/5G polymorphism was analyzed in normal group (121 individuals) and CHD group (126 cases) by a combination of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: The 4G allele and 4G/4G genotype frequencies of PAI-1 gene (0. 60 and 0. 397) for CHD patients were higher than those (0. 48 and 0. 190) for healthy controls (X2=7. 63, P2=12. 67, P0. 05), respectively. Conclusion: These results suggest that the PAI-1 4G/4G genotype is associated with an increased risk for CHD in Chinese patients. The subjects with the 4G/4G genotype had a higher prevalence of CHD, compared to those with the 5G/5G PAI-1 genotype.